Diessner J (33) discovered that tumor cell killing via ADCC increased when the triple combination of trastuzumab, pertuzumab, and NK cells was applied to HER2-positive breast cancer cells compared with the extent of ADCC induced by a single antibody. This evidence concerns the gene ERBB2 and breast carcinoma.